Diversified Trust Co Has $637,000 Position in Integra Lifesciences Holdings Corp (IART)
Diversified Trust Co increased its stake in shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) by 8.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,317 shares of the life sciences company’s stock after buying an additional 1,047 shares during the quarter. Diversified Trust Co’s holdings in Integra Lifesciences were worth $637,000 at the end of the most recent reporting period.
A number of other large investors also recently modified their holdings of IART. Pinebridge Investments L.P. lifted its stake in Integra Lifesciences by 2.2% during the second quarter. Pinebridge Investments L.P. now owns 7,971 shares of the life sciences company’s stock worth $435,000 after purchasing an additional 174 shares during the last quarter. Ameritas Investment Partners Inc. lifted its stake in Integra Lifesciences by 3.6% during the second quarter. Ameritas Investment Partners Inc. now owns 5,409 shares of the life sciences company’s stock worth $295,000 after purchasing an additional 187 shares during the last quarter. Public Employees Retirement System of Ohio lifted its stake in Integra Lifesciences by 0.5% during the second quarter. Public Employees Retirement System of Ohio now owns 55,635 shares of the life sciences company’s stock worth $3,033,000 after purchasing an additional 300 shares during the last quarter. Amalgamated Bank lifted its stake in Integra Lifesciences by 6.6% during the second quarter. Amalgamated Bank now owns 8,510 shares of the life sciences company’s stock worth $464,000 after purchasing an additional 524 shares during the last quarter. Finally, ETRADE Capital Management LLC lifted its stake in Integra Lifesciences by 4.3% during the second quarter. ETRADE Capital Management LLC now owns 14,941 shares of the life sciences company’s stock worth $814,000 after purchasing an additional 617 shares during the last quarter. 87.58% of the stock is currently owned by institutional investors and hedge funds.
Several equities research analysts have weighed in on IART shares. Zacks Investment Research upgraded Integra Lifesciences from a “hold” rating to a “buy” rating and set a $57.00 target price for the company in a research note on Tuesday, October 3rd. Oppenheimer set a $58.00 target price on Integra Lifesciences and gave the stock a “buy” rating in a research note on Tuesday, December 12th. TheStreet cut Integra Lifesciences from a “b” rating to a “c+” rating in a research note on Thursday, October 26th. Cantor Fitzgerald restated a “neutral” rating and set a $52.00 target price on shares of Integra Lifesciences in a research note on Friday, January 5th. Finally, Bank of America cut Integra Lifesciences from a “buy” rating to a “neutral” rating in a research note on Tuesday, January 2nd. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and three have assigned a buy rating to the company. The company has an average rating of “Hold” and an average target price of $52.70.
Integra Lifesciences (NASDAQ:IART) last announced its earnings results on Thursday, October 26th. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.47 by ($0.02). The company had revenue of $278.83 million for the quarter, compared to the consensus estimate of $286.00 million. Integra Lifesciences had a return on equity of 16.35% and a net margin of 4.52%. The firm’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same period in the prior year, the business earned $0.93 earnings per share. sell-side analysts predict that Integra Lifesciences Holdings Corp will post 1.85 earnings per share for the current fiscal year.
In related news, VP Richard D. Gorelick sold 1,500 shares of the firm’s stock in a transaction on Tuesday, November 14th. The stock was sold at an average price of $47.19, for a total transaction of $70,785.00. Following the completion of the transaction, the vice president now directly owns 21,665 shares of the company’s stock, valued at approximately $1,022,371.35. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Barbara B. Hill bought 10,768 shares of the stock in a transaction that occurred on Tuesday, October 31st. The shares were bought at an average cost of $46.66 per share, with a total value of $502,434.88. Following the completion of the transaction, the director now owns 55,540 shares in the company, valued at $2,591,496.40. The disclosure for this purchase can be found here. 21.50% of the stock is owned by company insiders.
About Integra Lifesciences
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra Lifesciences Holdings Corp (NASDAQ:IART).
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.